BioCardia CardiAMP for Chronic Myocardial Ischemia

Summary of the Provided Text:

This text is a ‍press release from BioCardia, Inc., a ⁣company focused on developing cellular and cell-derived therapies for cardiovascular and pulmonary diseases. here’s a breakdown ⁣of the key information:

* Company⁤ Focus: BioCardia develops therapies using a patient’s‍ own cells (autologous) and donor cells (allogeneic) too treat heart and lung ⁤conditions.
* Key Platforms:

* CardiAMP^® & CardiALLO™: Thier core biotherapeutic platforms.
* Helix™ & Morph^®: Platforms for ‍delivering these therapies and navigating within blood ⁢vessels.
* Heart3D™: An upcoming fusion imaging platform.
* Clinical Development: They have three cardiac product candidates currently in clinical trials.
* Partnerships: BioCardia collaborates with other⁤ companies developing biological therapies‍ to⁢ improve delivery methods.
* References to Existing research: The release cites four studies (ERICA, CARISA, MUST-EECP, and ⁣a 2018 European Heart Journal study) supporting the potential benefits of therapies addressing angina and improving heart function. These ⁢studies explore⁤ treatments like ranolazine and EECP, as well as CD34 ⁣cell therapy.
* Forward-Looking Statements: The release includes a disclaimer about “forward-looking statements,” ‍acknowledging⁣ risks and ⁣uncertainties related to their development programs, clinical trial success, and financial‍ projections.

In essence,⁢ BioCardia is positioning itself as a leader in ⁢innovative ⁤cell-based therapies for heart disease, building on existing research and developing its own proprietary platforms for treatment and delivery.

You can find more⁣ information at www.biocardia.com.